WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Reversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from 'extreme' patient biology first — TFN

Belgian techbio Sightera raises €3M to flip AI drug discovery, training its models on treatment-resistant patient biology before designing new molecules.

Raccontata datechfundingnews.comtech.eu

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
techfundingnews.comStai leggendo4 h fa

Reversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from 'extreme' patient biology…

Belgian techbio Sightera raises €3M to flip AI drug discovery, training its models on treatment-resistant patient biology before designing new molecules.

originale
tech.eu47 min fa

Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform

The funding will expand Sightera's AI-driven drug discovery platform, advance its lead oncology programme towards candidate selection, and strengthen partnerships with pharmaceutical companies.

Leggi questa versione → originale

Timeline cronologica

  1. venerdì 17 luglio 2026·techfundingnews.com

    Reversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from 'extreme' patient biology first — TFN

    Belgian techbio Sightera raises €3M to flip AI drug discovery, training its models on treatment-resistant patient biology before designing new molecules.

  2. venerdì 17 luglio 2026·tech.eu

    Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform

    The funding will expand Sightera's AI-driven drug discovery platform, advance its lead oncology programme towards candidate selection, and strengthen partnerships with…